FGFR2 and cholangiocarcinoma: The first evidence of FGFR2 fusions in iCCA patients was reported by Wu and colleagues in 2013 [53]; subsequently, an impressive number of studies have been published on this topic, also observing that etiology and geographical elements could modify the prevalence of FGFR aberrations in CCA.